Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TerumoTSE:4543 +1.13%91 EV-to-EBITDA is 11.90 as of Sep. 01, 2026, which is 33% below its 10-year median of 17.65. GuruFocus rates TSE:4543 with a GF Score™ of 91/100 and a GF Value™ of 円3,196.80 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 519 Medical Devices & Instruments companies, Terumo ranks better than 58.19% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Terumo's enterprise value is 円3,786,025 Mil.
Terumo's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was 円318,184 Mil. Therefore, Terumo's EV-to-EBITDA for today is 11.90.
The historical rank and industry rank for Terumo's EV-to-EBITDA or its related term are showing as below:
TSE:4543'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.27 Med: 17.65 Max: 31.18
Current: 11.9
During the past 13 years, the highest EV-to-EBITDA of Terumo was 31.18. The lowest was 10.27. And the median was 17.65.
TSE:4543's EV-to-EBITDA is ranked better than 58.19% of 519
companies
in the Medical Devices & Instruments industry
Industry Median: 14.48
vs TSE:4543: 11.90
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-09-01), Terumo's stock price is 円2544.50.
Terumo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was 円111.490. Therefore, Terumo's PE Ratio (TTM) for today is 22.82.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Terumo's share price for today is 円2544.50.
Terumo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円111.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Terumo's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4543 vs ISRG, BDX, RMD: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Terumo's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Terumo EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Terumo's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Terumo's EV-to-EBITDA falls into.
Terumo's current Enterprise Value is 円3,786,025 Mil.
Terumo's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円318,184 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Terumo (TSE:4543) has a EV-to-EBITDA of 11.90 as of Sep. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Terumo. This is 33% below median its historical median of 17.65. Over the past decade, Terumo's EV-to-EBITDA has ranged from 10.27 to 31.18. According to the industry distribution chart, Terumo ranks #217 out of 519 companies in the Medical Devices & Instruments industry, placing it in the top 41.8%.
Is Terumo's EV-to-EBITDA too high?
Terumo's current EV-to-EBITDA of 11.90 is 33% below median its 10-year median of 17.65. Over the past 10 years, this metric has ranged from a low of 10.27 to a high of 31.18. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.48. Terumo's value of 11.90 is 17.8% below this industry median. Based on the distribution chart, Terumo ranks #217 out of 519 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Terumo has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Terumo's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Terumo ranks #217 out of 519 companies for EV-to-EBITDA. This puts Terumo in the upper half of its industry. The industry median EV-to-EBITDA is 14.48. Terumo's value of 11.90 is 17.8% below this benchmark. Historically, Terumo's own EV-to-EBITDA has ranged from 10.27 to 31.18 over the past decade. While the company's 10-year median is 17.65 vs. the industry median of 14.48, Terumo has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.48, based on 519 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Terumo's current EV-to-EBITDA of 11.90 is 17.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Terumo. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Terumo's current EV-to-EBITDA is 11.90, which is 33% below median its own 10-year median of 17.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Terumo stock overvalued right now?
Based on GuruFocus' analysis, Terumo (TSE:4543) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,196.80, compared to a current price of 円2,544.50 — trading 20.4% below its estimated fair value. The current EV-to-EBITDA is 11.90, which is 33% below median its 10-year median of 17.65 and 17.8% below the Medical Devices & Instruments industry median of 14.48. Terumo's overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Terumo (TSE:4543), the current EV-to-EBITDA is 11.90 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Terumo (TSE:4543) Overvalued in 2026?
Based on GuruFocus' analysis, Terumo stock appears to be undervalued.
The current stock price of 円2,544.50 is trading 20.4% below its estimated GF Value™ of 円3,196.80.
GuruFocus considers Terumo to be Modestly Undervalued.
Key valuation signals for TSE:4543:
EV-to-EBITDA: 11.90 (33% below median its 10-year median of 17.65)
GF Value™: 円3,196.80 vs. price of 円2,544.50 (20.4% below fair value)
Industry Position: 17.8% below the Medical Devices & Instruments median (#217 of 519)
No single metric tells the full story. See the TSE:4543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2025, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 38% of Terumo's revenue.
91GF Score
Get the complete analysis for TSE:4543
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4543 has been successfully added to your 
